Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6614236 | PMC |
| http://dx.doi.org/10.1007/s11606-019-04863-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Challenges of sharing individual participant data for secondary research on neglected tropical diseases: the experience of Drugs for Neglected Diseases initiative and a call for action.
BMJ Open
December 2024
Drugs for Neglected Diseases initiative, Geneva, Switzerland
Introduction: The Drugs for Neglected Diseases initiative (DNDi) is committed to maximising the scientific value of the individual participant data (IPD) it has collected during its 20 years of activity and the IPD it will collect in the future, while safeguarding research participants' privacy and their right to know how their data will be processed.
Objective: The objective of this article is to share what DNDi has learnt while working on its commitment to data sharing. It also aims to advance the debate about best practice in the research community to avoid 'IPD sharing paralysis', with a focus on multistakeholder projects involving patients and researchers based in countries with various levels of data privacy regulations and measures.
Activity impairment, work productivity, health-related quality-of-life, and costs associated with uncomplicated urinary tract infection among females in Germany.
PLoS One
January 2025
Department of Epidemiology, GSK, Collegeville, Pennsylvania, United States of America.
Uncomplicated urinary tract infections (uUTIs) represent a sizable healthcare burden with a substantial negative impact on patients' health-related quality-of-life (HRQoL). However, the HRQoL impact of uUTI from the patient perspective is under-represented in research. A cross-sectional online survey assessed activity impairment and work productivity, HRQoL, costs, and treatment satisfaction of female patients with uUTIs in the US; the current study applies this earlier methodology to Germany to provide a European perspective.
View Article and Find Full Text PDFStakeholder perspectives on facilitators and barriers to implementing a zero-dollar copay program for chronic conditions study.
Health Res Policy Syst
January 2025
Department of Maternal and Child Health, University of North Carolina Chapel Hill School of Global Public Health, Chapel Hill, United States of America.
Background: Type 2 diabetes mellitus (T2D) remains a pressing public health concern. Despite advancements in antidiabetic medications, suboptimal medication adherence persists among many individuals with T2D, often due to the high cost of medications. To combat this issue, Blue Cross and Blue Shield of Louisiana (Blue Cross) introduced the $0 Drug Copay (ZDC) program, providing $0 copays for select drugs.
View Article and Find Full Text PDFCost effectiveness of empagliflozin in adult patients with chronic kidney disease in the Netherlands.
PLoS One
December 2024
Department of Health Sciences, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Aim: The recent EMPA-KIDNEY trial showed evidence for preventing disease progression in adult patients with chronic kidney disease (CKD) treated with empagliflozin. It is however yet unknown if use of empagliflozin is cost effective in the Netherlands. We aimed to evaluate the cost effectiveness of empagliflozin in adult patients with CKD in the Netherlands.
View Article and Find Full Text PDFCost of TB care and equity in distribution of catastrophic TB care costs across income quintiles in India.
Glob Health Res Policy
December 2024
ICMR-National Institute of Epidemiology (ICMR-NIE), R-127, TNHB, Ayapakkam, Chennai, Tamil Nadu, 600077, India.
Background: Tuberculosis (TB) poses a significant social and economic burden to households of persons with TB (PwTB). Despite free diagnosis and care under the National TB Elimination Programme (NTEP), individuals often experience significant out-of-pocket expenditure and lost productivity, causing financial catastrophe. We estimated the costs incurred by the PwTB during TB care and identified the factors associated with the costs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!